ГоловнаArchive of numbers2019Volume 27, issue 2 (99)Management of schizophrenia and bipolar disorder in pediatric practice
Title of the article Management of schizophrenia and bipolar disorder in pediatric practice
Authors Martsenkovskyi Igor
Martsenkovska Inna
In the section DIAGNOSTICS AND THERAPY OF MENTAL AND NARCOLOGICAL DISORDERS
Year 2019 Issue Volume 27, issue 2 (99) Pages 38-47
Type of article Scientific article Index UDK 616.895.8:616.89-057-071-08 Index BBK -
Abstract The article presents the features of diag nosis and treatment of schizophrenia and bipolar disorders (BD) with early manifestation in adolescence. Management of disorders includes the complex use of pharmacological, psychological treatment and special forms of social care. The treatment program should include the psychoeducation of the child and his parents and the mobilization of family support. The article also discusses the effi cacy of atypical antipsychotics (risperidone, aripiprazole, olanzapine) and mood stabilizers (valproate, lithium, lamotrigine, and carbamazepine) based on recommendations Food and Drug Administration (FDA) USA, European Medicines Agency (EMA) and the Expert Center of the Ministry of Health of Ukraine. The obtained results of own conducted controlled trials on the effi cacy and safety of olanzapine use are discussed by the authors. Since 2010, 22 cases of olanzapine (Zolafren®) use for adolescents with schizophrenia spectrum disorders aged 13—17 years have been registered in the department of mental disorders of children and adolescents at the Institute of Psychiatry of the Ministry of Health of Ukraine. The period of controlled administration for olanzapine at a dose of 5—20 mg per day ranged from 44 to 70 weeks. As a result of the study were highlighted clinical situations in which the characteristics of the olanzapine action profi le demonstrated its greater effi cacy compared to risperidone and conventional antipsychotics in adolescents. The aim of another controlled trial conducted by the Institute of Psychiatry of the Ministry of Health of Ukraine in 2015—2018 was to evaluate the efficacy of olanzapine at a dose of 5—20 mg per day in adolescents with fi rst time diagnosed acute manic/mixed episode of BD. Nine adolescents aged from 14 to18 years old were assigned. Olanzapine in dose 5 to 20 mg was an eff ective medication for treatment of acute/mixed affective episodes in adolescents with BD and was an acceptable alternative to conventional antipsycho tics and risperidone treatment. Various side eff ects were observed in patients receiving olanzapine therapy, the average number of side eff ects per patient was 2.86, while the most frequent side eff ect was weight gain.
Key words schizophrenia, bipolar disorder, antipsychotic medication, pediatric practice, children and adolescents
Access to full text version of the article pdf download
Bibliography


1. Schulz S. C., Goerke D. Schizophrenia in children and adolescents. The Medical Basis of Psychiatry / Fatemi S., Clayton P. (Eds.). New York : Springer, 2016. P. 447—456. URL: https://doi. org/10.1007/978-1-4939-2528-5_22.
2. Manning J. S. Tools to improve differential diagnosis of bipolar disorder in primary care // Primary care companion to the Journal of clinical psychiatry. 2010. Vol. 12 (Suppl 1). P. 17—22. DOI: 10.4088/PCC.9064su1c.03.
3. McClellan, J., Kowatch R., Findling R. L. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder // Journal of the American Academy of Child & Adolescent Psychiatry. 2007. Vol. 46. Suppl 1. P. 107—125. DOI: 10.1097/01.chi.0000242240.69678.c4.
4. Mosolov S. N., Kostyukova E. G., Ushkalova A. V. Problemyi diagnostiki i terapii bipolyarnoy depressii: ot dokazatelnyih nauchnyih issledovaniy k klini ches kim rekomendatsiyam // Biologi ches kie metodyi terapii psihi ches kih ras st roystv (dokazatelnaya meditsina — klini ches koy praktike) / pod red. prof. S. N. Mosolova. M., 2012. S. 529—553
5. Lee S., Matejkowski J. Associations between comorbid health conditions and the use of mental health services among adults with bipolar disorder // Social Work in Health Care. 2016. Vol. 55. Issue 1. P. 28—40. URL: https://doi.org/10.1080/009813 89.2015.1107016.
6. Burden of general medical conditions among individuals with bipolar disorder / Kilbourne A. M., Cornelius J. R., Han X. [et al.] // Bipolar disorders. 2004. Vol. 6. No. 5. P. 368—373. DOI: 10.1111/j.1399-5618.2004.00138.x.
7. The presentation, recognition and management of bipolar depression in primary care / Cerimele J. M., Chwastiak L. A., Chan Y. F. [et al.] // Journal of general internal medicine. 2013. Vol. 28. No. 12. P. 1648—1656. DOI: 10.1007/s11606-013-2545-7.
8. Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: Fink-Jensen A. [et al.] // Journal of Child and Adolescent Psychopharmacology. 2016. Vol. 26. No. 5. P. 410—427. DOI: 10.1089/cap.2015.0097.
9. Laakso L. J. Motivational interviewing: Addressing ambivalence to improve medication adherence in patients with bipolar disorder // Issues in mental health nursing. 2012. Vol. 33. No. 1. P. 8—14. DOI: 10.3109/01612840.2011.618238.
10. Motivational interviewing to increase cognitive rehabilitation adherence in schizophrenia / Fiszdon J. M., Kurtz M. M., Choi J. [et al.] // Schizophrenia bulletin. 2016. Vol. 42. No. 2. P. 327—334. DOI: 10.1093/schbul/sbv143.
11. Incidence of adverse events in antipsychotic-naive children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE) / Menard M. L., Thummler S., Giannitelli M. // BMJ Open. 2016. Vol. 6. Issue 4. P. e011020. doi: 10.1136/bmjopen-2015-011020.
12. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: a systematic review and network meta-analysis / Pagsberg A. K., Tarp S., Glintborg D. [et al.] // Journal of the American Academy of Child & Adolescent Psychiatry. 2017. Vol. 56. 56, Issue 3. P. 191—202. DOI: 10.1016/j.jaac.2016.12.013.
13. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis // BMJ. 2000. Vol. 321 (7273). P. 1371—1376. PMID: 11099280.
14. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis / Leucht S., Corves C., Arbter D. [et al.] // The Lancet. 2009. Vol. 373 (9657). P. 31—41. DOI: 10.1016/S0140-6736(08)61764-X.
15. Pearsall R., Glick I. D., Pickar D. A new algorithm for testing schizophrenia // Psychopharmacology bulletin. 1998. Vol. 34. No. 3. P. 349—353.
16. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia / McCue R. E., Waheed R., Urcuyo L. [et al.] // The British Journal of Psychiatry. 2006. Vol. 189. Issue 5. P. 433—440. DOI: 10.1192/bjp.bp.105.019307.
17. Davis J. M., Chen N., Glick I. D. A meta-analysis of the efficacy of second-generation antipsychotics // Archives of General Psychiatry. 2003. Vol. 60. No. 6. P. 553—564. URL: https://psycnet. apa.org/doi/10.1001/archpsyc.60.6.553.
18. Shoja Shafti S., Gilanipoor M. A comparative study between olanzapine and risperidone in the management of schizophrenia // Schizophrenia research and treatment. 2014. Vol. 2014, Article ID 307202, 5 pages. DOI: 10.1155/2014/307202.
19. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia / Lieberman J. A., Stroup T. S., McEvoy J. P. [et al.] // New England Journal of Medicine. 2005. Vol. 353. No. 12. P. 1209—1223. DOI: 10.1056/NEJMoa051688.
20. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics / Faries D., Ascher-Svanum H., Zhu B. [et al.] // BMC Psychiatry. 2005. Vol. 27. No. 5. P. 26. DOI: 10.1186/1471-244X-5-26.
21. Bipolar depression: overview and commentary / Baldessarini R. J., Vieta E., Calabrese J. R. [et al.] // Harvard Review of Psychiatry. 2010. Vol. 18. No. 3. P. 143—157. DOI: 10.3109/10673221003747955.
22. ECNP consensus meeting. Bipolar depression. Nice, March 2007 / Goodwin G. M., Anderson I., Arango C. [et al.] // European Neuropsychopharmacology. 2008. Vol. 18. No. 7. P. 535—549. DOI: 10.1016/j.euroneuro.2008.03.003.
23. Berk M., Dodd S. Efficacy of atypical antipsychotics in bipolar disorder // Drugs. 2005. Vol. 65. No. 2. P. 257—269. DOI: 10.2165/00003495-200565020-00006.
24. Tohen M. Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design // International Journal of Neuropsychopharmacology. 2017. Vol. 20. Issue 2. P. 95—97. DOI: 10.1093/ijnp/pyx002.
25. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder /Kowatch R. A., Suppes T., Carmody T. J., Bucci J. P. [et al.] // Journal of the American Academy of Child & Adolescent Psychiatry. 2000. Vol. 39. No. 6. P. 713—720. DOI: 10.1097/00004583-200006000-00009.
26. Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder / Findling R. L., Kafantaris V., Pavuluri M. [et al.] // Journal of child and adolescent psychopharmacology. 2011. Vol. 21. No. 3. P. 195—205. DOI: 10.1089/cap.2010.0084.
27. Schmitz B. Effects of antiepileptic drugs on mood and behavior // Epilepsia. 2006. Vol. 47. Suppl 2. P. 28—33. DOI: 10.1111/j.1528-1167.2006.00684.x.
28. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study / Kessing L. V., Hellmund G., Geddes J. R. [et al.] // The British Journal of Psychiatry. 2011. Vol. 199. No. 1. P. 57—63. DOI: 10.1192/bjp.bp.110.084822.
29. Tatum W. O. Use of antiepileptic drugs in pregnancy // Expert review of neurotherapeutics. 2006. Vol. 6. Issue 7. P. 1077—1086. DOI: 10.1586/14737175.6.7.1077.
30. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice / De Hert M., Dobbelaere M., Sheridan E. M. [et al.] // European Psychiatry. 2011. Vol. 26. No. 3. P. 144—158. DOI: 10.1016/j.eurpsy.2010.09.011.
31. McIntyre R. S., Jerrell J. M. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents // Archives of Pediatrics & Adolescent Medicine. 2008. Vol. 162. No. 10. P. 929—935. DOI:10.1001/archpedi.162.10.929.